Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q1 FY2026 Earnings Presentation
20 slides from Aurobindo Pharma's earnings presentation, August 2025
Slide 1: Aurobindo Pharma Limited Earnings Presentation Q1FY26
Aurobindo Pharma Limited Earnings Presentation Q1FY26
Slide 2: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 3: Table of Content
Table of Content 04 Q1FY26 Business & Financial Highlights 11 Update on Biosimilars 14 Financial Summary 13 17 Filings Snapshot 3
Slide 4: Q1FY26 Business & Financial Highlights
Q1FY26 Business & Financial Highlights 4
Slide 5: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q1FY26 ₹ 7,868 Cr ₹ 1,603 Cr ₹ 824 Cr Q1FY25 ₹ 7,567 Cr ₹ 1,620 Cr ₹ 918 Cr Y-o-Y growth % 4.0% (1.0%) (10.2%) 5
Slide 6: Business Highlights – Q1FY26
Business Highlights – Q1FY26 Revenue of ₹7,868 crores with 4.0% growth YoY, driven by strong Europe and Growth markets performance Reported EBITDA of ₹1,603 crores with a margin of 20.4%, driven by stable gross margins and operating efficiencies Net Capex of US$ 73 million* primarily towards capacit
Slide 7: Quarterly Performance – Q1FY26
Quarterly Performance – Q1FY26 Revenue (Rs Crore) US Revenue excluding Puerto Rico (US$ Mn) 8,382 470 7,979 435 7,868 432 7,796 426 421 7,580 7,567 408 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 EBITDA (Rs Crore) Net Debt to Equity 0.04 1,792 0.02 1,687 1,620
Slide 8: Consolidated Business Performance
Consolidated Business Performance ₹ Crores Q1FY26 Q1FY25 Y-o-Y (%) Q4FY25 Q-o-Q (%) USA** 3,488 3,555 -1.9% 4,072 -14.3% Europe 2,338 1,982 18.0% 2,147 8.9% Growth Markets* 772 709 8.8% 786 -1.8% ARV 355 229 55.2% 308 15.2% Total Formulations 6,953 6,475 7.4% 7,313 -4.9% Beta-lactam 633 791 -20.0% 7
Slide 9: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 480 470 • US revenue in Q1FY26 declined by 4% YoY 460 accounting for 44.3% of consolidated revenue 440 426 420 mainly on account of significant reduction in 408 400 lenalidomide sales 380 • Filed 4 AN
Slide 10: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Crore) 1,092 91 90 1,069 85 236 241 221 916 41 36 27 Q1FY25 Q4FY25 Q1FY26 Q1FY25 Q4FY25 Q1FY26 Q1FY25 Q4FY25 Q1FY26 Q1FY25 Q4FY25 Q1FY26 Growth Markets reported a YoY Europe business posted ARV business continue
Slide 11: Update on Biosimilars
Update on Biosimilars 11
Slide 12: Sustaining the momentum in biosimilars
Sustaining the momentum in biosimilars Dazublys, a trastuzumab biosimilar, received marketing authorization (MA) from European Commission (EC) CuraTeQ has three biosimilars approved by the EC MHRA granted MA for Dyrupeg, the third biosimilar to be approved by the Agency On track to make first commer
Slide 13: Continuing progress through an expanding pipeline in 2025-26
Continuing progress through an expanding pipeline in 2025-26 BP11, our biosimilar to Xolair, to complete Phase 3 study in patients with chronic spontaneous urticaria in Q3FY26 BP16, our biosimilar to Prolia, completed Phase 3 study in women with post-menopausal osteoporosis and on track for filing i
Slide 14: Financial Summary
Financial Summary 14
Slide 15: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement Rs Cr Q1FY26 Q1FY25 YoY Chg. (%) Q4FY25 QoQ Chg. (%) Revenue from Operations 7,868 7,567 4.0% 8,382 -6.1% Gross Profit 4,629 4,494 3.0% 4,954 -6.6% Gross Margin 58.8% 59.4% -56 bps 59.1% -27 bps Overheads -3,025 -2,875 5.2% -3,162 -4.3% EBITDA (before For
Slide 16: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-22 Mar-23 Mar-24 Mar-25 Jun-25 Closing Rate (INR/USD) 75.793 82.170 83.405 85.475 85.76 758 833 966 963 930 884 Fx Loan restated in INR 2,223 4,638 3,994 5,883 5,299 Rupee Loan 150 224 2,324 2,065 2,282 232 228 182 185 196 Gross Debt 2,373 4,8
Slide 17: Filing Snapshot
Filing Snapshot 17
Slide 18: US ANDA Filings Snapshot as on 30th June 2025
US ANDA Filings Snapshot as on 30th June 2025 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 157 29.3 Aurobindo (Excl. Specialty & 800 704 600 532 Specialty & Injectables 300 700 ARV 29 1.6 600 500 250 500 200 172 Injectables) 400 400 150 50.8 300 300 CVS 123 200 132 200 105 100 56
Slide 19: Global Regulatory Filing Details
Global Regulatory Filing Details As at As at As at As at As at As at As at As at As at Category Geography Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Jun 25 US* 478 541 586 639 727 774 830 861 865 Europe** 2,848 3,003 3,214 3,374 3,580 3,751 3,642 3,933 3,985 Formulations SA** 415 430 43
Slide 20: Thank You
Thank You For more information, contact: ir@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1211 20